Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound

Executive Summary

After several years of either niche or me-too drug launches, 2010 brought an encouraging wave of new molecular entities and novel biologics to market, including several first-in-class drugs addressing large therapeutic areas.

You may also be interested in...



A Call For Action: Integrating Payor Requirements Into Phase III Clinical Trials

The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.

A Call For Action: Integrating Payor Requirements Into Phase III Clinical Trials

The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.

For Brand Drugs, Doom And Gloom In 2010

With sluggish pharmaceutical sales growth due to generic uptake, fewer patient visits to doctors and less use of chronic medications - 2010 was a dismal year for brand drugs, IMS data show.

Related Content

Topics

UsernamePublicRestriction

Register

PS052975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel